These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 24471307)
1. [Expert consensus post-marketing evaluation scheme to detect immunotoxicity of Chinese medicine in clinical populations (draft version for comments)]. Xie YM; Zhao YB; Jiang JJ; Chang YP; Zhang W; Shen H; Lu PF Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2933-6. PubMed ID: 24471307 [TBL] [Abstract][Full Text] [Related]
2. [Technical specifications for intensive hospital safety monitoring of post-marketing Chinese medicine (draft version for comments)]. Xie YM; Liao X; Zhao YB; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Wen ZH; Yang ZQ; Zou JD; Sun HS; He Y; Li XL; Jiang JJ; Wang ZF; Li YY; Wang LX; Chang YP; Yang W; Zhang W Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2919-24. PubMed ID: 24471304 [TBL] [Abstract][Full Text] [Related]
3. [Technical specifications for post-marketing pharmacoeconomic evaluation of Chinese medicine (draft version for comments)]. Xie YM; Wang X; Wang N; Chang YP Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2925-9. PubMed ID: 24471305 [TBL] [Abstract][Full Text] [Related]
4. [Establishment of model of traditional Chinese medicine injections post-marketing safety monitoring]. Guo XE; Zhao YB; Xie YM; Zhao LC; Li YF; Hao Z Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2974-8. PubMed ID: 24471314 [TBL] [Abstract][Full Text] [Related]
5. [Exploration of how to formulate guidelines on post-marketing traditional Chinese medicine surveillance]. Zhang W; Xie YM; Yu WY Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2943-8. PubMed ID: 24471309 [TBL] [Abstract][Full Text] [Related]
6. [Postmarketing herbs clinical evaluation should concern about re-evaluating symptoms]. He W; Xie Y; Wang Y Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(11):1498-500. PubMed ID: 20822030 [TBL] [Abstract][Full Text] [Related]
7. [Expert consensus on population pharmacokinetics of Chinese medicine ( draft version for comments)]. Xie YM; Wang JN; He FY; Jiang JJ; Xiong X Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2937-42. PubMed ID: 24471308 [TBL] [Abstract][Full Text] [Related]
8. [Clinical orientation of post-marketing Chinese patent drugs: an evidence-based practice]. Shang HC; Zhang BL; Li YP Zhong Xi Yi Jie He Xue Bao; 2008 Sep; 6(9):887-90. PubMed ID: 18782528 [TBL] [Abstract][Full Text] [Related]
9. [Thought on several problems of post-marketing herbs clinical evaluation in special populations]. Zhou A; Lian F Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2776-8. PubMed ID: 22292362 [TBL] [Abstract][Full Text] [Related]
10. [Study on 10 409 cases of post-marketing safety Danhong injection centralized monitoring of hospital]. Li X; Tang J; Meng F; Li C; Xie Y Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2783-5. PubMed ID: 22292364 [TBL] [Abstract][Full Text] [Related]
11. ["Re-evaluation upon suspected event" is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations]. Wu SX; Sun HF; Yang XH; Long HZ; Ye ZG; Ji SL; Zhang L Zhongguo Zhong Yao Za Zhi; 2014 Aug; 39(15):2983-8. PubMed ID: 25423845 [TBL] [Abstract][Full Text] [Related]
12. [Comparison and analysis of clinical safety evaluation methods for parenterally administered Chinese medicine]. Yan BH; Peng C; Xie YM; Wang YY Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2979-82. PubMed ID: 24471315 [TBL] [Abstract][Full Text] [Related]
13. [Thought on several problems of clinical revaluation of post-marketing herb research]. He W; Xie Y; Wang Y Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(12):1641-3. PubMed ID: 20815225 [TBL] [Abstract][Full Text] [Related]
14. [Study on method on post-marketing traditonal Chinese medicine safety assessment]. Kou Q; Zhao S; Feng G; Xie Y Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2771-5. PubMed ID: 22292361 [TBL] [Abstract][Full Text] [Related]
15. [Survey on Xiaoke pill treating diabetes mellitus in small cities' Chinese medicine hospital for post-marketing surveillance]. Xie Y; Zhao Y; Liu H; Wang Y Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2859-61. PubMed ID: 22292385 [TBL] [Abstract][Full Text] [Related]
16. [A discussion of key issues on postmarketing reevaluation of Chinese medicine]. Xie Y; Tian F Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(11):1494-7. PubMed ID: 20822029 [TBL] [Abstract][Full Text] [Related]
17. [Technical specifications for rational clinical use of parenterally administered Chinese medicine (draft version for comments)]. Xie YM; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Zhao YB Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2930-2. PubMed ID: 24471306 [TBL] [Abstract][Full Text] [Related]
18. [Post-marketing reevaluation for potential quality risk and quality control in clinical application of traditional Chinese medicines]. Li HJ; He LY; Liu BY Zhongguo Zhong Yao Za Zhi; 2015 Jun; 40(12):2461-3. PubMed ID: 26591543 [TBL] [Abstract][Full Text] [Related]
19. [Technical specification for re-evaluation of post-marketing clinical effectiveness of traditional Chinese medicine (first draft)]. Zhao Y; Yang YY; Wang YX; Yang HM; Wu SX Zhongguo Zhong Yao Za Zhi; 2018 Aug; 43(15):3211-3215. PubMed ID: 30200720 [TBL] [Abstract][Full Text] [Related]
20. [Post-marketing clinical study of traditional Chinese medicine--lessons learned from comprehensive evaluation of Fufang Zaoren capsule]. Qing S; Gao L; Zhang L; Jia JP; Liu XM; Ji SL; Yang XH Zhongguo Zhong Yao Za Zhi; 2013 Nov; 38(21):3790-4. PubMed ID: 24494575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]